San Francisco, January 31st, 2018 – Recardio Inc. today announced that it has received the FDA approval for its Phase 2 study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction.
Recardio presented at BIO Investor Forum 2017 in San Francisco
San Francisco, Oct. 17, 2017 – Recardio presented today its clinical regenerative therapy program for cardiovascular diseases at the international BIO Investor Forum 2017 in San Francisco.
Recardio completes Phase 1 Study
San Francisco, October 12th, 2017 – Recardio Inc. successfully completes Phase 1 study for Dutogliptin.
Umbrella Patent for the treatment of cardiovascular diseases in the EU
San Francisco, Aug. 28th, 2017 – RECARDIO, announced that the European Patent Office (EPA) has issued the notice of allowance for its innovative use patent for the treatment of ischemic diseases.
Recardio at ESC 2017 – The European Society of Cardiology Congress
San Francisco, Jul. 25, 2017 – Recardio is participating in the European Society of Cardiology Congress in Barcelona.